Skip to navigationSkip to contentSkip to footerHelp using this website - Accessibility statement
  • EBOS Group Limited

    Diversified Australasian marketer, wholesaler and distributor of healthcare, animal care and medical and pharmaceutical products.

    EBO$32.110
     -0.010 -0.03%

    Data last updated:May 17, 2024 – 3.58pm. Data is 20 mins delayed.

    Previous Close

    32.120

    Open

    32.040

    Day Range

    31.825 - 32.290

    52 Week Range

    30.810 - 41.520

    Volume

    18,002

    Value

    577,975

    Bid

    32.110

    Ask

    32.180

    Dividend Yield

    2.98%

    P/E Ratio

    23.63

    Market Cap

    6.160B

    Total Issue

    193,237,006

    ASX Announcements

    NZX Capital Change Notice

    Issued Capital - Other

    • May 13, 2024
    • 2 pages

    Application for quotation of securities - EBO

    Appendix 2A (Application for Quotation of Securities)

    • May 13, 2024
    • 7 pages

    Macquarie Australia Conference Presentation

    Company Presentation

    • May 7, 2024
    • 31 pages

    EBOS announces appointment of new CFO

    Company Administration - Other

    • Apr 26, 2024
    • 1 page

    NZX Capital Change Notice

    Issued Capital - Other

    • Apr 12, 2024
    • 2 pages

    View all EBO announcements

    December 2023

    Chemist Warehouse looks set to become an ASX-listed company.

    Chemist Warehouse heads for the ASX via Sigma deal

    The billionaire Gance and Verrocchi families are eyeing an ASX berth through a reverse listing of their retail behemoth via Sigma Healthcare.

    • Updated
    • Carrie LaFrenz

    November 2023

    Investors are nursing losses and have wound back risk.

    Inside the $4b Greencross bellyflop – and what it means for deals

    Someone has cooked the golden goose, and fingers are pointing at underwriters, investors, private equity and advisers, after last week’s spectacular blow up.

    • Anthony Macdonald
    Greencross, which includes veterinary clinics, was to be sold in a $3.75b deal.

    Greencross’ $3.75b deal with EBOS dumped as investors lose bite

    The deal would have allowed EBOS to plunge deeper into pet care, after losing a key chemist supply contract.

    • Liam Walsh
    A Greencross vets location in Victoria.

    EBOS in $3.75 billion deal to buy Greencross; Macquarie, UBS on raise

    It’s down to the short strokes at ASX-listed pharma distributor EBOS’s tilt for TPG Capital’s pets and vets business Greencross.

    • Sarah Thompson, Kanika Sood and Emma Rapaport

    June 2023

    Chemist Warehouse has switched its supply contract from EBOS to Sigma Healthcare.

    Sigma Healthcare wins EBOS’s Chemist Warehouse contract

    Sigma Pharmaceuticals has won over the Chemist Warehouse wholesale pharmaceuticals contract held by its rival EBOS.

    • Sarah Thompson, Kanika Sood and Emma Rapaport
    Advertisement

    December 2021

    Street Talk.

    EBOS buys PEP’s Lifehealthcare, raising $742m

    Australasian health care group EBOS has acquired medical devices business Lifehealthcare for $1.167 billion, and is asking shareholders to tip into a $742 million raising to help fund it.

    • Anthony Macdonald, Yolanda Redrup and Kanika Sood

    August 2021

    Ebos CEO John Cullity is investing $80 million in a new state of the art pet food manufacturing facility in NSW.

    Ebos Group posts record 2021 result

    Ebos Group has posted another record result for the 2021 financial year, announcing double-digit earnings growth, and an $80 million pet food manufacturing facility.

    • Carrie LaFrenz

    July 2021

    Wesfarmers boss Rob Scott has been eyeing the health sector for a number of years, and hopes to build a new vertical in the conglomerate’s business.

    Wesfarmers’ API bid could be the start of a fresh shopping spree

    The $1.38 a share cash offer for Priceline owner API was classic Wesfarmers modus operandi, and was timed to perfection.

    • Sue Mitchell and Carrie LaFrenz

    June 2021

    ABS figures show that in 2020 we spent 35 per cent more time with our pets.

    How investors can play the booming pet trade

    The billions of dollars Australians spend on caring for and feeding their ‘fur babies’ is likely to have increased strongly over the past 18 months and is expected to continue.

    • Elio D'Amato

    February 2021

    Coles has emerged in stronger shape  from the pandemic.

    All the key profit results for February 17

    On the biggest day yet of the interim profit reporting season we have results from Coles, Westpac, Treasury Wines, Tabcorp, Charter Hall, Corporate Travel, Domino’s Pizza, Carsales, TPG, Super Retail Group, Netwealth, Asaleo Care, Bapcor, Pro Medicus, Pact Group, EBOS and McPherson’s. Find full reports and analysis here.

    John Cullity, CEO of health supplies giant EBOS Group, says so far this new half, the company is not experiencing any COVID-19 related setbacks.

    Pet care helps EBOS to record profit

    The wholesaler and distributor of healthcare, medical and pharmaceutical products increased its interim dividend and painted an upbeat outlook.

    • Carrie LaFrenz

    August 2020

    EBOS CEO John Cullity said the impact of COVID-19 on the business over 2020 was neutral.

    EBOS Group posts record earnings and profits

    The wholesaler and distributor of healthcare, medical and pharmaceutical products gained from its new contract with pharmacy giant Chemist Warehouse.

    • Carrie LaFrenz

    June 2020

    There's movement on the share register of $3.4 billion health supplies giant EBOS Group, run by John Cullity.

    Strategic bails on EBOS, Citi lines up fundies for $300m stake

    Stockbrokers Citi and Forsyth Barr were in the market with a big parcel of shares in EBOS Group late on Monday. 

    • Sarah Thompson, Anthony Macdonald and Tim Boyd
    Health Minister Greg Hunt has penned the 7th Community Pharmacy Agreement with the Pharmacy Guild.

    Government, pharmacies strike $1.2b deal on PBS

    The new deal provides certainty for the nation's 5,800 community pharmacies and will result in improved medication management and adherence programs and better access to over 200 million subsidised prescriptions each year.

    • Carrie LaFrenz

    November 2019

    JPMorgan has a new executive director in its Australian markets business.

    UBS in EBOS Holdings block trade, Sybos selling

    UBS' equities desk is in the market with a large block of EBOS shares on Monday afternoon. 

    • Sarah Thompson, Anthony Macdonald and Tim Boyd
    Advertisement

    April 2019

    Street Talk.

    EBOS placement upsized ahead of book close

    Dual-listed health care supplies company EBOS Group has upsized its equity raising, following response from investors. 

    • Sarah Thompson and Anthony Macdonald
    Street Talk.

    EBOS fronts funds for $NZ150m equity injection

    Kiwi health care supplies company EBOS is in front of fund managers seeking a $NZ150 million equity injection.

    • Sarah Thompson and Anthony Macdonald

    March 2019

    Sigma Healthcare chief executive Mark Hooper says he is confident with his  ability to deliver $100 million of savings. T

    Sigma's bottom line hit by restructuring, due diligence costs

    The pharmaceutical wholesaler is looking for $100 million savings as it reshapes its business ahead of the loss of key customer Chemist Warehouse.

    • Updated
    • Carrie LaFrenz

    December 2018

    Sigma Healthcare, API in merger talks

    Shares in pharmaceutical wholesaler Sigma Healthcare surged 45 per cent amid merger talks with rival API.

    • Carrie LaFrenz

    October 2018

    EBOS Group to buy balance of TerryWhite chain in $50m deal

    EBOS Group will buy out the balance of minority shares in pharmacy chain Terry White Group in a $50 million cash deal.

    • Updated
    • Carrie LaFrenz

    Copyright © 2024. Company information displayed on The Australian Financial Review is sourced from Morningstar and ASX and is subject to their terms and conditions as set out in our Terms of Use. The Australian Financial Review does not accept any responsibility for the accuracy and/or completeness of such data or information.